CHAPTER 3 66 Molecular POLE-mut 26 (9.8) 3 (7.1) 3 (10.7) 0 1 (3.3) MSI 51 (19.2) 15 (35.7) 2 (7.1) 4 (14.3) 6 (20.0) TP53-mut 31 (11.7) 9 (21.4) 8 (28.6) 16 (57.1) 8 (26.7) NSMP 157 (59.2) 15 (35.7) 15 (53.6) 8 (28.6) 15 (50.0) MI <50% 154 (58.1) 4 (9.5) 16 (57.1) 11 (39.3) 12 (40.0) >50% 111 (41.9) 36 (85.7) 12 (42.9) 17 (60.7) 18 (60.0) Missing 0 (0.0) 2 (4.8) 0 (0.0) 0 (0.0) 0 (0.0) LVSI No 219 (82.6) 27 (64.3) 26 (92.9) 14 (50.0) 18 (60.0) Yes 46 (17.4) 15 (35.7) 2 (7.1) 14 (50.0) 12 (40.0) Lymph nodes N0 231 (87.2) 42 (100.0) 0 (0.0) 16 (57.1) 16 (53.3) N1 23 (8.7) 0 (0.0) 0 (0.0) 8 (28.6) 12 (40.0) Pelvic 14 (60.9) 0 (0.0) 0 (0.0) 4 (50.0) 0 (0.0) Para-aortic 4 (17.4) 3 (37.5) 0 (0.0) Pelvic and para-aortic 5 (21.7) 0 (0.0) 0 (0.0) 1 (12.5) 0 (0.0) Unknown which nodes 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 12 (100.0) Nx 6 (2.3) 0 (0.0) 28 (100.0) 4 (14.3) 2 (6.7) FIGO stage Early (I-II) 223 (84.2) 42 (100.0) 13 (46.4) 12 (40.0) Advanced (III-IV) 42 (15.8) 0 (0.0) 28 (100.0) 15 (53.6) 18 (60.0) Adjuvant treatment None 66 (24.9) 12 (28.6) 4 (14.3) 6 (21.4) 9 (30.0) Radiotherapy 163 (61.5) 25 (59.5) 7 (25.0) 15 (53.6) 15 (50.0) EBRT 53 (32.5) 8 (32.0) 0 (0.0) 6 (40.0) 0 (0.0) VBT 72 (44.2) 12 (48.0) 0 (0.0) 5 (33.3) 0 (0.0) ERBT+VBT 38 (23.3) 5 (20.0) 0 (0.0) 4 (26.7) 0 (0.0) Unknown 0 (0.0) 0 (0.0) 7 (100.0) 0 (0.0) 15 (100.0)
RkJQdWJsaXNoZXIy MTk4NDMw